Bausch + Lomb Corporation (BLCO) AI Stock Analysis

• Market Cap: $4.87B
• Dividend Yield: N/A
• Average Volume (3M): 905.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: 8.81%
• EPS Growth: 40.43%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.07
• Shares Outstanding: 353,865,780
• 10 Day Avg. Volume: 1,133,718
• 30 Day Avg. Volume: 905,784
• PEG Ratio: -0.93
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 1.33
• P/FCF Ratio: -107.69
• Enterprise Value/Market Cap: 1.92
• Enterprise Value/Revenue: 1.91
• Enterprise Value/Gross Profit: 3.21
• Enterprise Value/Ebitda: 26.66
• 1Y Price Target: $14.50
• Price Target Upside: 2.33% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11

• Rating: 55 Neutral
• Price Target: $14.50 ▲(2.33% Upside)

Bausch + Lomb Corporation's overall stock score reflects a balance of positive growth prospects and significant profitability challenges. The raised financial guidance and strong performance in key segments are encouraging, but ongoing losses and cash flow issues weigh heavily. Technical indicators provide some support, but valuation concerns persist due to negative earnings.

Positive Factors

Financial Performance

Bausch + Lomb reported total revenue of $1,278M, representing a 5.1% year-over-year growth, beating the analyst's projection.

Growth Drivers

Miebo sales were a key growth driver, contributing significantly to overall BLCO growth with strong optimism for continued growth.

Revenue Guidance

Management has raised 2025 revenue guidance to $5,050-5,150M, corresponding to 5-7% constant currency growth.

Negative Factors

Competition

Miebo and Xiidra together saw a slight decline in their dry eye new prescription share in May, which could indicate increasing competition in the market.

Market Uncertainty

Investor interest will be limited until there is more visibility on the separation from Bausch Health.

Pricing Pressure

XIIDRA faced gross-to-net pricing pressure, which is believed to persist through the remainder of 2025.

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation (BLCO) is a leading global eye health company that focuses on the development, manufacturing, and marketing of a wide range of products. The company's core product categories include contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices and instruments. Serving both the consumer and the healthcare professional markets, Bausch + Lomb operates in sectors such as Vision Care, Pharmaceuticals, and Surgical, providing solutions aimed at improving vision and overall eye health.

How the Company Makes Money

Bausch + Lomb makes money through a diversified revenue model centered around its key product categories. The Vision Care segment generates revenue from the sale of contact lenses and lens care products, catering to both individual consumers and eye care professionals. The Pharmaceuticals segment includes prescription and over-the-counter products for the treatment of various eye conditions, contributing significantly to the company's earnings. The Surgical segment derives its income from the sale of ophthalmic surgical devices and instruments, which are used in procedures such as cataract surgery. Bausch + Lomb's revenue streams are supported by its global distribution network and strategic partnerships with healthcare providers and institutions, enabling it to maintain a strong presence in the eye health market.

Bausch + Lomb Corporation Financial Statement Overview

Summary

Bausch + Lomb Corporation demonstrates mixed financial performance. While revenue growth is positive, persistent net losses and negative profit margins indicate significant profitability challenges. The balance sheet is stable with moderate leverage, but negative returns on equity and weak cash flow generation highlight the need for strategic improvements.

Income Statement

The income statement shows a mixed performance for Bausch + Lomb Corporation. Over the TTM period, gross profit margin stands at 70.4%, indicating effective cost management. However, the net profit margin is negative at -11.78%, reflecting significant losses. Revenue growth is positive at 2.25%, but profitability remains pressured with negative EBIT and EBITDA margins of 0.74% and 5.16%, respectively. The company needs to address its declining profitability despite revenue growth.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.77, indicating moderate leverage. Return on equity is negative at -8.93% due to net losses, and the equity ratio is solid at 46.55%. The company has managed to maintain a balanced structure despite increasing liabilities, but negative returns on equity highlight a need for improved profitability.

Cash Flow

Cash flow analysis reveals challenges in cash generation. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is -0.32, suggesting insufficient cash flow relative to net losses. The free cash flow to net income ratio is negative, indicating inefficiencies in turning earnings into cash flow. Improvement in operational efficiency is crucial to enhance cash flow performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.89B	4.77B	4.15B	3.77B	3.77B	3.41B
Gross Profit	2.92B	2.92B	2.50B	2.25B	2.30B	2.13B
EBITDA	351.00M	614.00M	512.00M	599.00M	762.00M	739.00M
Net Income	-401.00M	-317.00M	-260.00M	15.00M	182.00M	-17.00M
Balance Sheet
Total Assets	13.83B	13.47B	13.44B	11.14B	10.82B	11.27B
Cash, Cash Equivalents and Short-Term Investments	272.00M	305.00M	331.00M	354.00M	174.00M	238.00M
Total Debt	4.96B	4.78B	4.56B	2.44B	112.00M	101.00M
Total Liabilities	7.32B	6.92B	6.52B	4.04B	1.42B	1.28B
Stockholders Equity	6.44B	6.47B	6.85B	7.03B	9.33B	9.92B
Cash Flow
Free Cash Flow	-165.00M	-59.00M	-198.00M	170.00M	664.00M	263.00M
Operating Cash Flow	186.00M	232.00M	-17.00M	345.00M	873.00M	522.00M
Investing Cash Flow	-487.00M	-412.00M	-2.11B	-215.00M	-214.00M	-256.00M
Financing Cash Flow	247.00M	178.00M	2.08B	81.00M	-712.00M	-232.00M

Bausch + Lomb Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Positive. The current price of 14.17 is above the 20-day moving average (MA) of 14.00, above the 50-day MA of 13.23, and below the 200-day MA of 15.39, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 56.24 is Neutral, neither overbought nor oversold. The STOCH value of 38.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLCO.

Bausch + Lomb Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	76 Outperform	$41.48B	29.80	25.86%	0.76%	9.84%	37.48%
COO	73 Outperform	$14.50B	35.26	5.15%	―	6.88%	21.11%
STAA	56 Neutral	$1.36B	55.81	-25.55%	―	-32.59%	-667.81%
BLCO	55 Neutral	$4.87B	―	-4.22%	―	8.81%	40.43%
BAX	54 Neutral	$12.32B	136.07	-3.30%	3.32%	-27.41%	67.01%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
XRAY	49 Neutral	$2.60B	―	-37.78%	4.62%	-5.78%	-445.83%

Bausch + Lomb Corporation Corporate Events

Bausch + Lomb Amends CEO Employment Agreement

On July 21, 2025, Bausch + Lomb Corporation amended the employment agreement with CEO Brenton L. Saunders, limiting his severance rights related to the company’s spin-off from Bausch Health Companies Inc. Additionally, the company adjusted the terms of Saunders’ performance stock units, setting a new vesting schedule and performance targets to be achieved by February 23, 2029, which could impact the company’s financial incentives and executive compensation strategy.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Expands Note Offering to €675 Million

On June 18, 2025, Bausch + Lomb Corporation announced an increase in its offering of senior secured floating rate notes to €675 million, up from €600 million, with the proceeds intended to refinance existing loans and credit facilities. The company is also seeking to establish a $2.325 billion new term B loan facility and a new $800 million revolving credit facility, with both expected to close on June 26, 2025, to further strengthen its financial position.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600M Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company aims to secure a $2.2 billion new term B loan facility and a new $800 million revolving credit facility to refinance existing loans and support general corporate purposes. The transactions, subject to market conditions, are designed to strengthen the company’s financial structure but are not guaranteed to be completed as planned.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Shareholders Approve Executive Compensation

At the Annual Meeting of Shareholders on May 21, 2025, Bausch + Lomb Corporation‘s shareholders voted on three proposals. The election of directors resulted in the appointment of several individuals to the Board of Directors, who will serve until the 2026 Annual Meeting. Additionally, the shareholders approved the executive compensation on a non-binding advisory basis.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb’s New Board Agreements Announced

On May 19, 2025, Bausch Health Companies Inc., the majority shareholder of Bausch + Lomb Corporation, entered into letter agreements with the Icahn Group, Paulson Group, and Kavanagh Group. These agreements stipulate that if any of these groups engage in specified actions, they must resign from the boards of both Bausch Health and Bausch + Lomb. The agreements also include provisions for voting on board nominees, aiming to maintain stability in board representation.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.